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I N T R O D U C T I O N  
Adenosine deaminase (adenosine aminohydrolase, ADA, EC 3.5.4.4) is a 
purme catabohc enzyme which catalyzes the irreversible hydrolytic deamma-  
tion of adenosine to produce mosine and equally as well catalyzes the 
conversion of deoxyadenosine to deoxymosine (1). Whale ADA activaty is 
widely distributed in human ussues, ats acuvity as notably highest in lymphoid 
tissues, such as thymus, spleen, lymph nodes as well as circulating peripheral 
blood lymphocytes (2-6). 
A geneuc deficaency of ADA has been causally associated with an 
autosomal recessive form of severe combined immunodeficaency disease, 
resulting in profound T cell dysfunction and variable, but usually mild, B cell 
immunosuppression (7). In an attempt to define the molecular mechamsms m 
ADA deficaency disease, studies in v t t ro  have revealed that the maturation of 
precursor T lymphocytes is inhibited by an ADA mhibator while immature B 
lymphocytes are unaffected (8, 9). Also, the combination of deoxyadenosme 
and an ADA inhabator leads to the selective accumulation of dATP and 
cytotox~city xn cultured T lymphoblasts but not m B lymphoblasts (10), 
thereby mamxckmg the ADA deficaency disease. A high level of deoxynucleo- 
ude degrading enzyme(s) m B lymphoblasts appears to protect these cells from 
accumulating toxic levels of dATP (11-13). 
An associated, but less well understood, observation is that T cells or thexr 
precursors appear  to be highly dependent on ADA activity for protectxon 
against deoxyadenosme tox~caty and for normal cell maturation. Indeed, 
several studies have shown the level of ADA activaty to be markedly elevated 
specifically m these T cells For example, ADA actwlty ~s 3- to 10-fold 
elevated m normal thymocytes as compared to ammature B lymphocytes (4-6, 
14, 15) and ts 2- to 10-fold higher m T lymphoblasts cultured from patients 
wRh acute lymphoblastac leukemxa than m cultured B lymphoblasts (5, 14, 
16-21). 
Possible causes for the elevated levels of ADA activity m T lymphoblasts 
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might include an alteration in the catalytic or physical propemes of the 
enzyme or might lm, olve reduction or stablhzatlon of the enzyme In this 
study, we have sought an explanation for the different levels ot ADA 
expressed in cultured human T and B lymphoblast cell hnes bs' examining the 
physical and kinetic propemes of the enzyme and measuring its rate ol 
synthesis and degradation m these two cell types 
M A T E R I A I .  S A N D  M E T H O D S  
Materials 
[8-14C] Adenosine (59 mCi /mmol)  and [UJ4C] deoxyadenoslne (500 
mCl /mmol)  were purchased from Amersham/Searle .  Protosol, L-[35S] 
methionlne ( 1000-1100 C1/mmol) and 1251-labeled goat anti-rabbit lgG ( 1330 
Cl/mmol)  were obtained from New England Nuclear. Human erythrocyte 
ADA and human kidney ADA binding protein were purified to homogeneity 
and rabbit antiserum was prepared against each protein by previously 
described methods (22-25) The ADA binding protein was lodinated with 
carrier-free 12Sl as previously described (25). All other reagents used were of 
the highest quality commercially available 
Lymphoblast Cell Lines 
The T lymphoblast  cell lines, MOLT-4,  RPMI-8402, CCRF-CEM and 
CCRF-HSB-2,  were obtained from Hem Research (Rockville, MD). B 
lymphoblast  cell lines, GM-130, GM-131, GM-333, GM-621 and GM-1078, 
were purchased from the Human Genetic Mutant  Cell Repository (Camden, 
N J), while the cell hne, MGL-8, has been previously described (10). 
A ssal's 
Determinations of ADA enzyme activity, ADA immunoreactwe protein, 
and total lymphoblast  protein as well as assays for the Km for substrates, K, for 
the product, inoslne, S20w, and heat stability of ADA have been described (26). 
Labehng Procedures for L.vmphoblasts 
T and B lymphoblasts were harvested during mid-log phase growth and 
washed in growth medium (RPMI  containing 10% horse serum and 2mM 
glutamine). Cells were resuspended at 1 × 106cells/ml in growth medmm 
containing 10-40 ~CI /ml  L-[35S]methionine (1 #M) (depending on the cell hne 
and the experiment) and incubated at 37 ° in an atmosphere of 5% CO 2 and air 
Cells were labeled for varying periods up to 12 hr, then harvested. Cell 
suspensions were freeze-thawed 5 times, dialyzed 1/1000 v /v  m 10mM 
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Tris/HC1, pH 7.4 overnight, and centrifuged at 100,000 × g for 20 mm 
(Beckman Alrfuge) to yteld a soluble protein cell extract. 
For pulse-chase experiments, T and B cells were pulse labeled for 8 to 12 hr 
in growth medium containing [35S]methionme as described above, washed 
twice in growth medium and resuspended at 0 7-0.8 x 10 6 cells/ml m growth 
medium containing 2 mM non-radioactwe meth~omne Cells were harvested at 
various time intervals and extracts were prepared as above. 
Isolation and Analysts of  Labeled Lymphoblast A DA 
[35S]-Labeled cell extract (either T or B cell extract) was incubated for 
15 min at 37 ° with a 5-fold molar excess of ~251-bindmg protein to produce a 
tight binding complex with the labeled lymphoblast  ADA. The [35S]ADA- 
~251-binding protein complex was isolated after native polyacrylamide gel 
electrophoresis (7.5%, pH 8.9) and subsequently lmmunopreclpitated with 
either ant i -ADA serum or anti-binding protein serum as described (26). The 
lmmunoprecipitated [35S]ADA-l:5I-binding protein complex was subjected 
to sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis; the gel 
was then shced, extracted with a Protosol solution and analyzed for 
radioactwity in a toluene-based scintillation fluid (26). 
R E S U L T S  A N D  D I S C U S S I O N  
Properttes of  A DA in Cultured T and B Lymphoblasts 
Several commercially avadable human T and B lymphoblast  cell lines were 
harvested during mid-log phase of growth and analyzed for ADA actwlty. As 
shown in Table 1, the level of ADA activity was similar in cell extracts of 6 
unrelated normal B cell lines with a mean enzyme specific activity of 
'72 n m o l / m i n / m g  (range 66-81). In the 4 different T cell lines studied, the level 
of ADA activity differed by 2-fold, ranging in specific actwity from 475 to 
1064 nmol /min /mg .  The level of ADA activity in these T cell lines was 
elevated by approximately 7- and 14-fold over that in the B cell lines, 
comparable with previous reports (14, 19-21). 
In order to determine whether the elevated ADA activity in T cells might be 
due to enzyme activation or an altered molecular form of the enzyme, the 
kinetic and physical properties of the enzyme in T cells were compared to that 
in B cells. In all T and B cell lines, the enzyme exhibited a similar Km for 
adenosine (55-70 #M), and deoxyadenosme (50--70/~M), K, for mosme (600- 
700 #M) and Vmax using adenosine. Enzyme assay of mixtures of T and B 
lymphoblast  cell extracts indicated that the quantity of ADA activity 
expressed was additive, suggesting the absence of any endogenous mhibxtors 
or enzyme activators in these cell extracts. Analysis of all T and B lymphoblast 
cell extracts by sucrose density gradient centrifugation showed that all of the 
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TABLE 1 ADENOSINE DEAMINASE IN CULTURED 
HUMAN LYMPHOBLAST CELL LINES 
Sp Act CRM *+ Abs Sp Acts ~ 
kymphoblast nmol,' mln ng ADA CRM #mol /mm 
Cell Lines* mg cell prot mg cell prot mg ADA CRM 
B cell 72 5: 5* 132 -t- 1 I 545 • 15 
normal (6) (66-81 ) ( 122-149) 
T cell 
MOLT-4 1064 5:89 1940 + 132 548 5:22 
RPMI-8402 965 ± 52 1803 5:150 535-+ 14 
CCRF-CEM 501 5:32 969 :t: 100 520 5:23 
CCRF-HSB-2 4755:12 8 9 0 5 : 2 7  5345:15 
*Protein concentration of lymphoblast extracts ranged from 6-12 mg: ml Number of normal 
B lymphoblast cell hnes examined indicated m parentheses 
*Mean-t-S D (six determinations and 2 harvests of each cell line) Range 
given in parenthesis 
*tThe abbreviation CRM means lmmunologically cross reactive material 
~Absolute specific activity of ADA was calculated b) dividing the specific 
act l~l ty(nmol/mln/mg) by the n g C R M / m g  (From Ref 26) 
ADA activity was present at an S20w ranging from 3.6 to 3,9. These values were 
consistent with an $20~ of 3 8, previously calculated for purified human 
erythrocyte ADA (Mr ~- 38,000) (22) 
The charge properties of T and B cell ADA were examined using urea 
lsoelectric focusing gel electrophoresls. As shown in Figure l, purified human 
erythrocyte ADA, added as a standard, exhibits 3 prominent immunoreactlve 
bands detectable by autoradlography after binding with antl-ADA rabbit lgG 
and ~251-1abeled goat anti-rabbit IgG. These lmmunoreactive bands are 
similar in distribution and relative intensity to the lsozymes previously 
described for the erythrocyte enzyme using either non-denaturing lsoelectric 
focusing or polyacrylamide gel electrophoresis (2, 22) Figure 1 also shows 
that under this assay condition, the representative T cell extracts, RPMI-8402 
and CCRF-CEM, and the B cell extracts, MGL-8 and GM-130, exhibit only 
one apparently Identical ADA lmmunoreactive band corresponding to the 
most basic erythrocyte ADA lsozyme 
The level of ADA immunoreactive protein termed CRM was determined in 
all lymphoblast cell extracts by radlolmmunoassay. As shown in Table 1, the 
level of ADA lmmunoreactlve protein in T lymphoblast cell lines was 
markedly elevated by approximately 7- and 14-fold over that in the B cell 
lines However, in all cell lines, the amount of enzyme protein was found to be 
directly proportional to the enzyme activity as noted from the calculated 
absolute specific activity of the enzyme (Table 1). These data then suggest that 
the high steady-state level of ADA in T cells probably arises from changes in 
its rate of synthesis and /or  degradation relative to B cells. 
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FIG. 1 Urea lsoelectnc focusing gel of ADA Crude T and B lymphoblast cell extracts and 
purified erythrocyte ADA were lsoelectrlc focused under denaturing conditions and electro- 
phoretieally transferred to nitrocellulose paper lmmunoreactwe ADA was detected after binding 
rabbtt anti-ADA lgG and t251-goat-antl-rabbit IgG by autoradiography. A T-cell, RPMI-8402, 
B T-cell, CCRF-CEM, C purified erythrocyte ADA, D B-cell, MGL-8, E. B-cell, GM-130. 
(From Ref. 26). 
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Isolatton and Analysis of Labeled Lymphoblast ADA 
Measuring the turnover of ADA in cultured T and B lymphoblasts using 
immunoprecipitation techniques was difficult due to the small amount of 
ADA protein present in these cells The enzyme was found to represent only 
0 19 to 0 09% of total protein in the T cell hnes studied and only 0.01% of total 
soluble cell protein m B lymphoblasts. Preliminary trials to directly 
immunopreclpitate ADA from a [35S]methlomne-labeled T or B lymphoblast 
extract were generally unsuccessful as judged by SDS-gel analysis. A major 
contaminant was demonstrated to co-lmmunoprecipitate and co-migrate with 
ADA after gel electrophoresis. Thus, a purification step for ADA isolation 
was designed for use prior to lmmunopreclpitatlon, utdlzmg the complexa- 
tion of ADA with a specific ADA binding protein (25). This complex 
formation was found to stabdize ADA catalytic actlvtty allowing for both a 
purification and good recovery (85-90%) of the enzyme after native 
polyacrylamide gel electrophoresxs. The formauon of this ADA complex with 
a ~25I-labeled binding protein also provided a convenient means of detecting 
the location of the enzyme complex in the polyacrylamide gel by gamma 
counting and further the ~2Sl-actwity could serve as an internal standard for 
assessing recovery of the complex in the subsequent ~mmunoprec~p~tatlon 
step and SDS-gel analysis (26). 
Controls, demonstrating the speclficny of lymphoblast ADA immuno- 
preclpitatxon, are shown m Figure 2. The [35S]ADA-125I binding protein 
complex was purified from a representative T cell extract, CCRF-CEM, by 
native polyacrylamide gel electrophoresis, immunoprecip~tated wxth antibody 
and then analyzed after SDS-gel electrophoresis as described (26). As shown 
m F~gure 2A, when the isolated labeled ADA complex is immunoprecip~tated 
with anti-ADA serum, only two radioactive peaks are apparent after SDS-gel 
electrophoresis (closed circles). The subumt molecular wexghts are approxi- 
mately 94,000 and 40,000 corresponding to the dissocmted subumt of 1251- 
binding protein and [35S]ADA, respectively. When a 100-fold excess of 
purified erythrocyte ADA is added to the labeled extract prior to 
immunoprecipitat~on, the SDS-gel profile reveals that both peaks of 
radioactwity are prevented from binding to the antibody (Fig 2A, open 
circles). 
In an attempt to further identify the radioactive peak at Rf 0.60 as T cell 
ADA, lmmunoprecipitation of gel-purified [35S]ADA-t25I-bmding protein 
complex was performed using anti-ADA binding protein serum. As shown m 
Figure 2B, again only two peaks of radioactivity are detected with subunit 
molecular weights of 94,000 and 40,000 (closed circles). Note that the peak of 
radioactivity corresponding to the putative [35S]ADA, Rf 0.60 is quanma- 
tlvely the same as observed in Figure 2A. However, the peak size of the 1251- 
binding protein subunit (Rf 0.2) is increased, presumably reflecting the ability 
of the antibody to quantitatively immunoprecipitate ~25I-binding protein 
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FIG 2 Controls for specfflc,ty of ADA lmmunoprec~pltatlon CCRF-CEM, T-lymphoblasts 
(2 x 106 cells) were labeled for 12 hr m R PM 1 medmm containing 10% horse serum and 10 gC,/ml 
[~SS]methlonme (I /.LM final concentrauon) The [~SS]ADAJ2Sl-bmdmg protein complex was 
formed and isolated from the crude T-cell extract by naUve polyacrylamlde gel electrophoresls 
The enzyme complex was then immunopreclpltated using ant,body and analyzed after SDS-gel 
electrophorests The figures show the radloacuve SDS-gel profile after ,mmunoprec,pltat,on A 
with anU-ADA serum (o - -  e) and antiserum m the presence of a 100-fold excess of unlabeled 
purified ADA (O --  O), and B with anu-bmdmg protein serum (o - -  e)and ant,serum m the 
presence of a 100-fold excess of unlabeled purified binding protein (O - -  ©) Subumt molecular 
we.ght markers are phos a, phosphorylase a, BSA, bovine serum albumin, OA, ovalbumm and 
CT, chymotrypsmogen (From Ref 26) 
whether  free or  associated with A D A .  When a 100-fold excess of  unlabeled 
purified human h d n e y  A D A  bmding  pro tem is added to the labeled extract  
pr ior  to lmmunoprec ip t t a t lon ,  both radioact ive peaks are prevented from 
bmdlng  to the an t ibody (Fig 2B, open circles). In thts case, the binding 
protein an t ibody only recognizes the ~25I-labeled b lndmg protein port ion of 
the [35S]ADA-~ZSI-bmdtng protein complex  and does not cross-react with the 
A D A  por t ton  of  the complex .  
Thus the polyacrylamxde gel purif icat ion step in combina t ion  with ant ibody 
immunoprec ip l t a t l on  was completely  effective in isolating apparent ly  
homogeneous  lymphoblas t  A D A  and allowed an unambtguous  quant i ta t lon  
of [3-~S]ADA from labeled T cell extract .  Similar  results were also obtained 
using labeled B cell extracts  (data not shown). 
Turnover of  L.)'mphobla~t A DA 
Using the cell labehng and enzyme isolat ion techniques described, the 
apparent  rates of  A D A  synthesis and degradat ion  were determined m 
representat ive B and T cell lines By rad lo lmmunoassay ,  the B cell lines 
studied, GM-130 and MGL-8,  were each shown to have an equal  quant i ty  of 
A D A  protein while the T cell lines, C C R F - C E M  and RPMI-8402,  had a level 
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of enzyme protein which was elevated by 7- and 14-fold, respectively, over that 
in the B cell lines 
As noted xn Figure 3A, the apparent relative rate of  A D A  synthesis was 
found to be similar in both B cell hnes, GM-130 and MGL-8, (375 
d p m / d p m ×  10 6 total protein/hr). However,  while both T cell lines, CCRF- 
CEM and RPMI-8402, showed the same apparent relative rate of  A D A  
synthesis (800 d p m / d p m  × 10 6 total protein/hr), this rate was found to be 2- 
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FIG 3 Apparent rate oflymphoblast ADA synthesis A Representative T-cell hnes, RPMI-8402 
and CCRF-CEM, and B-cell hnes, MGL-8 and GM-130, were labeled with [3SS]methlonlne for 
xanous time periods and the [~S]ADA isolated and quantified as described m Fig 2 Each Ume 
point represents thc mean of 4 experiments per cell hne performed m duphcate B Apparent rate 
of lymphoblast ADA degradation The T and B cell lines noted above were pulse labeled w~th 
['~S]methlonlne for 12 hr, resuspended m chase medium and ahquots of cells were removed at 
speclhed time intervals The [35S}ADA was isolated and quantified as described The initial dpm 
of [3~S]A DA were between 3000 and 5000 at the beginning of the degradatton period for all cell 
lines stud~ed Each time point represents the mean of 3 experiments per cell hne performed in 
duphcate (From Ref 26) 
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being c o m p a r e d  in different  cell types,  the appa ren t  rate of [35S]methlonlne 
i so tope  i nco rpo ra t i on  into A D A  was normahzed  by express ing it as a 
percentage  of  the rate of  i nco rpo ra t i on  into to ta l  soluble cell prote in  for each 
cell hne examined .  This no rma l i za t ion  would  correct  for  any differences 
between cell types in the rate of i so tope  up take  or In d i lu t ion of  i sotope specific 
r a&oac t lv i ty  by endogenous  unlabeled meth ion lne  
When  the a p p a r e n t  rate of  A D A  degrada t ion  was examined  (F~g 3B), both 
B cell hnes showed a s imilar  appa ren t  rate of  enzyme deg rada t ion  with a tl, ~, of  
a p p r o x i m a t e l y  7 and 9 hr, while between the T cell lines a 2-fold rate difference 
was observed with a tk~ of  19 hr for C C R F - C E M  and 39 hr for RPM1-8402 
Thus,  respectively the T lymphob la s t  cell lines showed a p p r o x i m a t e l y  a 3- and 
0-fold s lower rate of  A D A  deg rada t i on  relat ive to that  in the B cell lines Thus,  
f rom a l te ra t ions  in both  the appa ren t  rate of enzyme synthesis and 
degrada t ion ,  the T cell lines s tudied exhib i ted  a 6- and 12-fold dlfferencc in net 
tu rnover  of A D A  relative to B- lymphob las t  cell lines consis tent  with the 
observed differences in enzyme act ivi ty  
The a p p a r e n t  differences in the rate of  enzyme deg rada t ion  between the T 
cell lines and a m o n g  the T and B cell lines could not  be ra t ional ized by any 
s t ructura l  differences in the A D A ,  since the size of  the pro te in  and its 
lsoelectr lc  pH were identical  in all cell lines. As well, there was no evidence of 
any  difference in the s tabi l i ty  of  the enzyme in these cell extracts  as measured 
by m v i t ro  heat labi l i ty The poss ibi l i ty  still exists that  A D A  may exhibi t  a 
different  m v l v o  s tab ih ty  toward  pro teases  m T than in B cells due to 
in t race l lu lar  c o m p a r t m e n t a t l o n  or  in teract ion with specific cel lular  hgands  
Al ternat ive ly ,  but  less likely, different  levels of a specific A D A  protease  in T 
and B cells may  account  for the al tered rates of enzyme degrada t ion  These 
and o ther  possibi l i t ies  remain  to be explored  
We next  sought  to de te rmine  whether  the express ion of A D A  in 
lymphob las t s  could  be a l tered by metabohc  effectors T and B lymphob las t  
cell lines, at  an ini t ial  cell densi ty  of  3× 105 ce l l s /ml ,  were individual ly  
cul tured for 72 hr ei ther  a lone  or  in the presence of  an addi t ive  and cell 
ahquo t s  were analyzed at 24-hr intervals  Under  the condi t ions  of  this 
exper iment ,  the level of  A D A  act ivi ty  and. /or  immunoreac t ive  prote in  in both 
T and B cells was unchanged  when these cells were cul tured in the presence of  
ei ther the A D A  substra tes ,  adenos ine  or deoxyadenos ine  (1 raM), the 
p roduc t s  of  the A D A  reaction~ lnoslne or deoxymosxne  (5 mM) or  the A D A  
i nh i b i t o r ,  e r y t h r o - 9 - ( 2 - h y d r o x y - 3 - n o n y l ) a d e n l n e  (0.01 mM). F u r t h e r ,  a 
selected g roup  of  lmmunosuppres s ive  drugs,  including dexamethasone ,  
hydrocor t l sone ,  and p redn iso lone  (tested at a final concen t ra t ion  of  0 1 raM) 
also faded to change the s teady-s ta te  level of A D A  act ivi ty  in these cells Thus,  
the different  levels of  A D A  observed in T and B cells could not  be 
exper imenta l ly  cont ro l led  in our  cell cul ture  system suggesting that  the 
enzyme was under  strict genetic regula t ion  
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SUMMARY 
High levels of adenosine deammase (ADA) activity have been associated 
with normal T cell differentiation and T cell disease, such as acute 
lymphoblastic leukemia; however, possible mechamsms controlhng the level 
of this enzyme have not been explored. In this study, the properties and rate of 
turnover of ADA are compared in cultured human T and B lymphoblast cell 
hnes (1) Relative to B lymphoblasts, the level of ADA actwity m extracts ofT 
lymphoblast cell lines (MOLT-4, RPMI-8402, CCRF-CEM and CCRF- 
HSB-2) is elevated 7- to 14-fold and differs by 2-fold among the T-cell lines. (2) 
In T and B lymphoblast extracts, the enzyme ~s apparently identical based on 
Km for adenosine and deoxyadenosine, Kl for inosme, Vmax for adenosine, 
S20w, lsoelectric pH, and heat stabdity. Further, by radiolmmunoassay the 
quantity of ADA immunoreactive protein is proportional to the level of 
enzyme activity m all cell lines studied. (3) Using a purification and selectwe 
immunoprecip~tation technique, the enzyme turnover could be assessed in cell 
lines labeled with [35S]methionine. The apparent rate of ADA synthes~s, 
relative to total protein, is 2-fold faster m both T cell lines (RPMI-8402 and 
CCRF-CEM) than in the B cell lines (MGL-8 and GM-130) The apparent 
half-hfe (ty2) for the enzyme degradation is 19 and 39 hr, respectively, for 
CCRF-CEM and RPMI-8402, whale the t,/2 for both B cell hnes is 7-9 hr. From 
the net rate of synthesis and degradation, the T cell lines exhibit a 6- and 12- 
fold difference m ADA turnover relative to B cells, consistent with the 
observed differences in enzyme activity. (4) The level of ADA (activity and/or  
protein) m cultured T or B lymphoblasts is not influenced by either substrates 
or products of the ADA reaction or an ADA inhibitor or a selected group of 
immunosuppressive drugs added to these cells in culture. 
These studies indicate that while ADA ~s apparently identical m all T and B 
lymphoblasts, alterations in both the rate of ADA synthesis and degradation 
lead to its accumulation and high steady-state level in T cells. 
ACKNOWLEDGEM ENTS 
Th~s investigation was supported by FHS Grant number CA26284 awarded 
by the National Cancer Institute, DHHS. 
REFERENCES 
1 E J CONWAY and R COOKE, The deammases of adenosine and adenyhc acid m blood 
and tissues, Btochem J 33, 479-492 (1939) 
2 M B VAN DER WEYDEN and W N KELLEY, Human adenosine deammase 
distribution and properties, J Btol Chem 251, 5448-5456 (1976) 
3 A ADAMS and R A HARKNESS, Adenosine deammase activity m thymus and other 
human tissues, Chn Exptl lrnmunol 26, 647-649 (1976) 
162 P E D A D D O N A a n d  W N KELLEY 
4 R l U N G ,  R SILBER, F QUAGLIATA, M CONKLYN, J GOTTESMAN and 
R HIRSCHHORN,  Adenosine deammase activity in chronic lymphocytic leukemia 
relationship to B- and T-cell subpopulatlons, J Chn lnvesttg 57, 756-761 (1976) 
5 J F SMYTH and K R HARRAP, Adenosine deammase activity in leukaemJa, Brlt J 
Cancer 31, 544-549 (1975) 
6 R HIRSCHHORN, F MARTINIUK and F S ROSEN, Adenoslnedeamlnaseactlv~t~ 
in normal tissues and t~ssues from a child w~th severe combined lmmunodeflclency 
and adenosine deamxnase deficiency, Chn Immunol Immunopathol 9, 287-292 
(1978) 
7 E R GIBLETT, J E ANDERSON, F COHEN, B POLLARAandH J MEUWISSEN, 
Adenosme-deamlnase deficiency m two patients with severely impaired cellular immunity, 
Lancet 2, 1067-1069 (1972) 
8 J -J BALLET, R INSEL, E MERLER and F S ROSEN, lnhtbmon of maturation 
of human precursor lymphocytes by coformycm, an inhibitor of the enzyme adenosine 
deammase, J E,:ptl Med 143, 1271-1276 (1976) 
9 H A SIMMONDS,  G S PANAYIandV C O R R I G A L k ,  Aroleforpurlnemetabohsmln 
the immune response adenosme-deammase actwlty and deoxyadenoslne catabolism 
Lancet 1, 60-63 (1978) 
10 B S MITCHELL, E MEJIAS, P E DADDONA and W N KELLEY, Punnogenlc 
lmmunodeflclency diseases selective toxicity of deoxyrlbonucleosldeS for T cells, 
Proc Nail Acad Sol U S A  75, 5011-5014 (1978) 
I1 D A CARSON, J KAYE, S MATSUMOTO, J E SEEGMILLERandL THOMPSON, 
Biochemical basis for the enhanced susceptlbdlty of human malignant T cell lines 
to deoxyrlbonucleostdes, Proc Nail Acad. Sct U S A 76, 2430-2433 (1979) 
12 R k WORTMANN, B S MITCHELL, N L EDWARDS and 1 H FOX, 
Basis for dlfferentml deoxyadenosine toxicity to T- and B-lymphoblasts a role 
for 5'-nucleotldase, Proc Nail Acad Sct U S A  76, 2434-2437 (1979) 
13 D A CARSON. J KAYE and D B. WASSON, The potential ~mportance of 
soluble deoxynucleotldase activity m mediating deoxyadenoslne toxlClt3, in human 
lymphoblasts, J lmmunol 126, 348-352 (1981) 
14 M S COLEMAN and J J HUTTON, Terminal deoxynucleotldyl transferase and 
adenosine deamlnase m human lymphoblast cell lines, E~;ptl Cell Res 94, 440-442 (1975) 
15 R BARTON, F MARTINIUK, R H1RSCHHORN and 1 GOLDSCHNEIDER, 
The d~stnbutmn of adenosine deammase among lymphocyte populations m the rat, 
J Imrnunol 122, 216--220 (1979) 
16 J MEIER, M S COLEMAN and J J HUTTON, Adenosine deammase activity 
m peripheral blood cells of patients with haematologlcal mahgnancles, Brtt J Can~er 
33, 3!2-319 (1976) 
17 J F SMYTH, D G POPLACK, B J HOLIMAN, B G LEVENTHAL and 
G YARBRO, Correlation of adenosine deammase activity w~th cell surface markers m 
acute lymphoblasttc leukemia, J Chn lnvestlg 62, 710-712 (1978) 
18 M S COLEMAN, M F GREENWOOD, J J HUTTON, P HOLLAND. B 
LAMPKIN, C KRILL and J E KASTELIC, Adenosine deamlnase, terminal 
deoxynucleotldyl transferase (TdT), and cell surface markers m chddhood acute leukemia, 
Blood 52,1125-1131 (1978) 
19 J L SULLIVAN, W R A OSBORNE and R J, WEDGWOOD, Adenosine 
deamlnase actlwty in lymphocytes, Brtt J Haematol 37, 157-158 (1977) 
20 B E CHECHIK and J MINOWADA. Quantltation of human thymus-leukemia- 
associated antigen m established hematopoletlc cell hnes by radlolmmunoassa,,, J ~/atl 
Cancer lnst 63, 609-614 (1979) 
21 G L TR1TSCH and J MINOWADA, Differences in purme metabohzlng enzyme 
actlvmes in human leukemia T-cell, B-cell and null cell lines brief commumcatmn, 
J Nail Cancer lnst 60,1301-1304 (1978) 
22 P E DADDONA and W N. KELLEY, Human adenosine deammase purification and 
subunlt structure, J Btol Chem 252, 110-115 (1977). 
23 P E DADDONA and W N KELLEY,  Human adenosine deamlnase binding protein 
assay, purification and properties, J Btol Chem 253, 4617-4623 (1978) 
HUMAN LYMPHOBLAST ADENOSINE DEAMINASE 163 
24 P E DADDONA, M A FROHMAN and W N KELLEY, Radlolmmunochemlcat 
quantltatlon of human adenosine deamlnase, J Chn lnvesttg 64,798-803 (1979) 
25 P E DADDONA, M A F R O H M A N a n d W  N KELLEY, Humanadenosmedeammase 
and ~ts binding protein m normal and adenosine deamlnase-deficlent fibroblast cell stratus, 
J Btol Chem 255, 5681-5687 (1980) 
26 P E DADDONA, Human adenosine deammase properties and turnover m cultured 
T and B lymphoblasts, J Btol Chem 256, 12496 12501 (1981) 
